Globus Medical (NYSE:GMED) Issues FY 2026 Earnings Guidance

Globus Medical (NYSE:GMED) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 4.700-4.800 for the period, compared to the consensus estimate of 4.470. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.2 billion.

Globus Medical Stock Down 4.7%

Shares of GMED stock traded down $4.17 on Thursday, reaching $85.05. The stock had a trading volume of 2,906,424 shares, compared to its average volume of 1,221,776. The firm’s 50-day moving average is $90.00 and its two-hundred day moving average is $86.47. The firm has a market capitalization of $11.50 billion, a price-to-earnings ratio of 21.59, a P/E/G ratio of 2.10 and a beta of 1.00. Globus Medical has a 12 month low of $51.79 and a 12 month high of $101.40.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The business had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, sell-side analysts forecast that Globus Medical will post 4.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Wells Fargo & Company upgraded shares of Globus Medical to a “strong-buy” rating in a report on Wednesday, March 18th. Needham & Company LLC raised their target price on shares of Globus Medical from $112.00 to $114.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Truist Financial set a $115.00 price target on shares of Globus Medical in a research note on Wednesday, February 25th. Finally, Piper Sandler restated an “overweight” rating and set a $115.00 price objective (up from $90.00) on shares of Globus Medical in a research report on Thursday, January 8th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $104.36.

Insider Activity at Globus Medical

In related news, EVP Kelly Huller sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total transaction of $1,890,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 18.38% of the company’s stock.

Institutional Investors Weigh In On Globus Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in GMED. Quadrant Capital Group LLC acquired a new position in shares of Globus Medical in the third quarter valued at approximately $148,000. UMB Bank n.a. lifted its holdings in shares of Globus Medical by 23.1% in the 4th quarter. UMB Bank n.a. now owns 1,512 shares of the medical device company’s stock worth $132,000 after purchasing an additional 284 shares in the last quarter. CIBC Private Wealth Group LLC boosted its position in Globus Medical by 36.1% during the fourth quarter. CIBC Private Wealth Group LLC now owns 1,217 shares of the medical device company’s stock worth $106,000 after purchasing an additional 323 shares during the period. Parallel Advisors LLC lifted its holdings in Globus Medical by 95.5% during the 4th quarter. Parallel Advisors LLC now owns 1,089 shares of the medical device company’s stock worth $95,000 after purchasing an additional 532 shares in the last quarter. Finally, Mark Sheptoff Financial Planning LLC bought a new position in shares of Globus Medical in the fourth quarter valued at approximately $79,000. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.